Estrogen receptor α is expressed in the majority of breast cancers and promotes estrogen-dependent cancer progression. 
INTRODUCTION
Breast cancer causes the most frequent women cancer prevalence and mortality in the world [1] . Up to 70% breast cancer cases are driven by estrogen receptor α (ERα) and anti-estrogen based therapy bring significant survival benefits for breast cancer patients [2] . However, about half of endocrine treated patients endure relapse, making it a significant clinical problem [3] . Thus, it is urgent and necessary to understand the potential mechanisms and insight into the novel facets and modulatory factors for estrogen signaling, which could serve for the development of promising treatment strategies.
Several mechanisms were shown to account for hyper-activation of ERα and endocrine resistance in breast cancer [4] [5] [6] . Some are related to crosstalk of other oncogenic signaling including HER2, EGFR and NF-κB pathway [4, 7] . The others are associated with the modulatory factors, which could include ERα co-activators and protein modulators, including ubiquitination, SUMOlyation and phosphorylation [8] [9] [10] . However, the detailed mechanism that how ERα protein and its signaling are controlled by these modulators still remains largely unclear. As a group of ubiquitin ligases have been shown to facilitate estrogen signaling in breast cancer cell, such as BRCA1, CHIP and RNF31, it may suggest ER signaling and turnover is tightly linked to ubiquitin-proteasome system [11] [12] [13] [14] .
The ERα protein stability and turnover could be controlled by several ubiquitination manners [15] . Interestingly, the ubquitinated ERα does not necessary lead to decreased protein stability [16] . For example, ERα mono-ubiquitination causes increased protein stability and enhanced ERα signaling activity [13] . However, the cellular factors that trigger and recognize this type of modification need to be further characterized. Our current study identifies the ubiquitin associated protein SHARPIN (Shank-Interacting protein-like 1, SIPL1) as a novel ERα modulation factor. SHARPIN was firstly cloned from nerve cells and was found to endure gene amplification in several human cancers, including breast tumor [17] [18] [19] . However, its function in breast carcinogenesis and estrogen signaling remains to be addressed. Here, we identify SHARPIN to control ERα ubiquitination and stability and thereby the transcriptional regulation of ERα target genes and breast cancer cell proliferation.
RESULTS

SHARPIN is higher expressed in breast tumor and correlates with ERα protein in breast cancer tissues
By analysis of TCGA public available database (https://tcga-data.nci.nih.gov/), we observe that SHARPIN mRNA level in breast cancer tissue is higher than normal breast tissue ( Figure 1A) , and SHARPIN mRNA level in breast cancer tissue is more likely to be higher compared with the adjacent normal breast tissue in individual breast cancer subtype ( Figure 1B) . In order to analyze the correlation between SHARPIN expression and breast cancer subtype markers, 133 breast tumor tissues are collected and immunohistochemistry (IHC) is applied for examine the protein level of SHARPIN, ERα, progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2). The control staining is in Figure 1C . The pathological character and lymph node status data are also collected. The IHC results show that SHARPIN expression is positively correlated with ERα in clinical samples (Table 1) . Then we measure the SHARPIN expression in both ERα positive cell lines (MCF-7 and T47D) and ERα negative cell lines (BT549 and MDAMB231) by western blot. Immuno-blotting shows that SHARPIN is ubiquitously expressed in both ERα positive and negative cell lines (Supplementary Figure 1A) .
SHARPIN facilitates ERα signaling and relates to poor prognosis in ERα positive breast cancer patients
Through analysis of the public available breast cancer survival data (http://kmplot.com/analysis/), we observe that SHARPIN expression correlates with poor relapse-free survival in ERα positive breast cancer patient groups of GSE 7390 dataset, GSE6532 dataset and GSE17705 dataset (Figure 2A) . In GSE1456 dataset, although the P value shows no statistically significant, the same trend can be observed as the other two datasets. To approach the function of SHARPIN in breast cancer cells in an unbiased way, we analyzed changes in previously generated global gene expression profiles following SHARPIN depletion in MCF-7 breast cancer cells (Assessing number: GSE77261). The pathway enrichment analysis reveals that SHAPRIN depletion significantly changes several pathways, including ERα and PTEN ( Figure 2B and Table 2 ). The regulatory effect of SHARPIN on PTEN/AKT was reported in previous and is observed from our RNA-sequence data [20] . By specific analysis of ERα signaling, we observe a group of ERα activating target genes are decreased, including ERα itself, while another group of ERα suppressing target genes are increased, such as CDKN1A and CDKN1B ( Figure 2C and Table 3 ). These RNA sequence data indicate that SHARPIN might play a supportive role in ERα signaling.
SHARPIN controls ERα signaling in breast cancer cells
In order to confirm the SHARPIN function in ERα signaling, we deplete SHARPIN by two individual siRNAs ( Figure 3A and 3B). SHARPIN depletion significantly decreases ERα protein level in MCF7 and T47D cells ( Figure 3C and Supplementary Figure 1B) . However, SHARPIN depletion does not significantly change PR and HER2 protein level (Supplementary Figure  1C and 1D) . In order to rule out the P53 regulatory effect on ERα protein, we double deplete both SHARPIN and P53. SHARPIN and P53 double depletion still manifests ERα protein decrease, which indicates that the regulatory role of SHARPIN on ERα protein is independent of P53 pathway (Supplementary Figure 1E) . By examining ERα target genes, we find that SHARPIN depletion significantly decreases ERα classic target genes (PS2, PKIB and IL20) in both vehicle and estradiol (E2) treated condition ( Figure  3D ). By checking the estrogen response element (ERE) activity, it shows that inhibition of SHARPIN decreases with relapse free survival in ER+, tamoxifen treated patients stratified for high (red) and low (black) SHARPIN expression levels in GSE7390 dataset (n = 198; optimized cut-off; Probe 220973_s_at: HR = 1.98; 95% CI: 1.24-2.88; P = 0.0028); GSE6532 dataset (n = 69; optimized cut-off; Probe 220973_s_at: HR = 2.6; 95% CI: 1.02-6.6; P = 0.037) and GSE17705 dataset (n = 196; optimized cut-off; Probe 220973_s_at: HR = 1.78; 95% CI: 1.02-3.10; P = 0.039). In GSE1456 dataset (n = 62; optimized cut-off; Probe 220973_s_at: HR = 2.45; 95% CI: 0.97-6.22; P = 0.051), although the P value shows no statistically significant, the same trend can be observed as the other two datasets (date: 2016-09-20). (B) Schematic graph shows significantly changed signaling by SHARPN depletion in MCF7 cells. The pathway-enrichment analysis was used by the threshold P<0.001 and fold change>2 to derive regulated genes. (C) The heat-map graph shows the ERα regulating genes, which is significantly changed by SHARPIN depletion in MCF-7 cells. 
SHAPRIN promotes E2-stimulated proliferation in breast cancer cells
To investigate the role of SHARPIN in cell proliferation, we utilize ERα-positive breast cancer cell MCF7 as a model. We deplete SHARPIN in MCF7 cells, while ERα depletion is used as the positive control ( Figure  4A ). The WST-1 assay shows that depletion of SHARPIN significantly decreases cell proliferation compared with siControl group ( Figure 4A ). Besides, SHARPIN depletion also decreases cell growth in T47D cells (Supplementary Figure 2C) . The ethynly-deoxyuridine (EdU) incorporation assay shows that depletion SHARPIN decreases EdU positive cells, which is similar as ERα depletion ( Figure 
SHAPRIN associates with ERα both in cytoplasm and nuclear, but does not transcriptionally facilitates ERα signaling
The cytoplasmic and nuclear separation assay shows that SHARPIN is mainly localized in the cytoplasm ( Figure 5A ). Interestingly, 20 minutes of E2 treatment could promote the trans-location of SHARPIN from cytoplasm into nucleus ( Figure 5B ). Immuno-precipitation (IP) shows that SHARPIN could associate with ERα both in the cytosol and nucleus ( Figure 5C and 5D). The trans-location of SHARPIN is further confirmed by immunocytochemistry ( Figure 5E ). However, there are two possibilities for SHARPIN effect on ERα signalingtranscriptional regulation or protein regulation. We deplete SHARPIN and collect mRNA and protein as early as 24 h. The ERα mRNA and protein level are both decreased at this time point ( Figure 5F ). Then, this give rises to two possible models that SHARPIN may regulate ERα gene expression by co-occupied with ERα on the target gene promoter regions. Seven promoters are identified from ERα gene, while it is already known that promoter A and B is commonly active in MCF-7 cells [21] . We perform chromatin immuno-precipitation (ChIP) by SHARPIN antibody, while ERα based ChIP is used as the positive control. However, SHARPIN based ChIP fails to detect the promoter binding of ERα and its classical target genes, such as IL20 and PKIB ( Figure 5G and 5H).
SHARPIN stabilizes ERα protein possibly through mono-ubiquitinating ERα at K302/303 sites
Since SHARPIN does not regulate ERα in transcription level, we infer that SHARPIN might regulate ERα through post-translational mechanisms. Upon inhibition of protein synthesis by cycloheximide, the presence of SHARPIN significantly prolongs the half-life of ERα protein in HEK293 cells ( Figure  6A, Supplementary Figure 5 ). With the treatment of proteasome inhibitor MG132, we observe the decrease of expected poly-ubiquitin chains in the presence of SHARPIN ( Figure 6B ). By applying ubiquitin plasmid with all lysine mutants (Ub KO), we find that SHARPIN increases the mono-ubiquitinated ERα ( Figure 6C ). This Figure 6F ).
DISCUSSION
In The relationship between estrogen signaling and breast cancer was revealed since 1934 [22] . The further discovery showed the significant benefit for ERα antagonists in breast cancer treatments [23] . However, endocrine resistance is still a big problem for ERα target therapy [24] . Interestingly, most of the endocrine resistance tumors are still ERα positive. Breast cancer cells get endocrine resistance through ERα modifications, including phosphorylation, ubiquitination and acetylation, to overcome the blocking effect by ERα antagonists [25, 26] . Even the post-translational modifications spread in ERα protein, only a few sites affect the ERα function, such as the modifications in the hinge domain of ERα [27] [28] [29] . The modifications in the hinge domain of ERα could affect the protein conformation and subsequent ligand/DNA binding affinity [30] . Quite a few studies have shown several key modification sites for ERα activity, including lysine 302/303 and serine 305 [31, 32] . For example, the p21-activated kinase family proteins were shown to facilitate ERα signaling by phosphorylating S305 site, increasing protein stability and promoting tamoxifen resistance [8, 33] . Besides, mono-ubiqutiination on K302/303 sites was also shown to promote ERα protein stability and ERα signaling activity [34] . Here, our research firstly identified the ubiquitin binding protein SHARPIN and its possible link for K302/ K303 modification with tamoxifen resistance. We believe that the novelly found ERα modifiers will not only help to understand the complexity of ERα signaling, but also increase the knowledge of less known ubiquitin binding proteins in nuclear receptor function.
SHARPIN protein was firstly found from nerve cells and characterized as the SHARK-interaction protein [17] . Further studies revealed that SHARPIN could associate with integrin and inhibit cell migration [35] . One of the most important finding is that SHARPIN is necessary for intact immune response. SHARPIN was shown to be the component of linear ubiquitin assembly complex (LUBAC) and facilitate NF-κB signaling transduction [36] . SHARPIN depletion will impair the linear ubiquitination of IKKr, which will cripple the P65/P50 translocation into the nuclear [37] . Phenotypically, SHARPIN knockout mice present with chronic proliferative dermatitis and impaired B and T cell development [38] [39] [40] . However, less is known about SHARPIN function in human cancer, even it endure a high gene amplification in TCGA database, such as pancreatic cancer and breast cancer (http:// www.cbioportal.org). Interestingly, our study reveals that SHAPRIN is not only higher expressed in breast cancer, but also correlates with ERα protein level and poor tamoxifen response. Besides, our study further shows SHARPIN involves in ERα mono-ubiquitination at K302/303 sites, which is a novel ubiquitination manner for SHARPIN protein. Although our previous study showed another component-RNF31 could also promote ERα mono-ubiquitination in breast cancer cells, the RNF31 modification effect on ERα is not dependent on the Ubiquitin-associated domain (UBA), which is necessary for LUBAC formation. Thus, we believe that SHARPIN mono-ubiquitinates ERα, which is independent of RNF31 or LUBAC function [13] .
In the study, we examine the role of SHARPIN in ERα positive breast cancer cells. SHARPIN is shown to associate ERα protein and prolong its stability via mono-ubiquitination at ERα hinge domain. Since the ERα signaling is required for breast cancer proliferation, modulation of ERα protein could be an approach to inhibit breast cancer cell progression and restore endocrine resistance. Besides, our unpublished data also shows SHARPIN promotes several oncogenic pathways, including hypoxia induced factors and AKT pathways. In all, SHARPIN could be a promising therapeutic strategy for breast cancer treatment.
CONCLUSIONS
This study identifies the first time, the ubiquitin binding protein SHARPIN as a modulator of ERα signaling in human breast cancer cells. Importantly, SHARPIN depletion could rescue tamoxifen sensitivity, hamper estrogen-dependent cell proliferation and decrease ERα signaling in multiple breast cancer cell lines. As a novelly discovered modulator for ERα signaling, SHARPIN could be a promising target to overcome endocrine therapy resistance.
MATERIALS AND METHODS
Cell culture
MCF-7 and HEK293 cells were cultured in DMEM (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (Invitrogen) at 37°C in a humidified atmosphere of 5% CO 2 in air. T47D cells were cultured in RPMI 1640 (Invitrogen) supplemented with 10% FBS (GIBCO) and 1% penicillin/streptomycin. Plasmids SHARPIN (pcDNA-Flag-SHARPIN) construct was kindly presented from Dr. Kazuhiro Iwai and was previously described. The pcDNA3-ERα plasmid, HAubiquitin-KO plasmid, the ERE-TK-luciferase reporter and the pRL-TK control were described in previous study [13] . The ERα 302/303 mutants (lysine to alanine) were described in previous paper [16, 37] . 
siRNA and plasmids transfection
RNA extraction and real-time PCR analysis
RNeasy kits were used to extract total RNA (Qiagen). Real-time PCR was performed as previously described. 36B4 was used as internal control. Primer sequences for Real-time PCR are provided in Supplementary Table.
Quantification of cell viability
MCF-7 and T47D cells were transfected with siSHARPIN or siControl in 24-well plates. After 24 h, the cells were seeded into 96-well plates. Estrogen and vehicle were added in each group. Cell numbers were determined using the WST-1 cell proliferation reagent as previously described [8] .
Flow cytometry
For ethynly-deoxyuridine (EdU) labeled DNA stain, cells were transfected with siSHARPIN, siERα and siControl. After 24 h, 10 nM estradiol or vehicle was added for another 24 h. Then 10 μM EdU was added into each plate for the last 60 min. For propidium iodide staining, MCF7 cells were seeded into 10-cm dishes. After 24 h, cells were transfected with siSHARPIN, siERα and siControl. After another 24 h, cells were fixed with 70% ethanol for 30 min and stained with propidium iodide. For the ERα rescue experiment, MCF7 cells were seeded into 10-cm dishes. After 24 h, cells were transfected with siSHARPIN, and siControl. After another 24 h, siSHARPIN group was transfected with 5 ug ERα plasmid, while other groups were transfected with 5 ug Flag vector. The BD LSR II flow cytometer (BD Bioscience) was used to measure the flow fluorescence intensity. www.impactjournals.com/oncotarget
Western blotting
Cells were lysed with RIPA lysis buffer. Anti-ERα (HC-20, SC543) was from Santa Cruz Biotechnology. Anti-SHARPIN (AB69507), and anti-FLAG (M2, ab48763) were acquired from Abcam. Anti-actin (8H10D10) was acquired from Cell Signaling Technology.
Immunoprecipitation
Immunoprecipitation was performed as previous described [41] . 100 ug cell lysls were pre-cleared with Rabbit IgG for 2 h and subsequently incubated with SHARPIN antibody (AB69507) over night, while rabbit Ig G was used as the negative control. The bounded protein was analyzed by ERα antibody (1DO5, santa cruz). For the overexpression experiment, HEK293 cells were transfected with 5 ug Flag-SHARPIN and ERα plasmid in 10 cm dish. Cell lysates were pre-cleared with IgG and subsequently incubate with Flag antibody or ERα antibody, while rabbit IgG was used as the negative control. The bound proteins were analyzed by western blotting.
Protein stability assays
HEK293 cells (10 5 ) were seeded into 24 well plates and transfected with 0.5 ug ERα plasmid together with 0.5 ug Flag-SHARPIN or empty Flag vector. After 48 h, cells were treated with 100 uM cycloheximide for indicated time points. Samples were subject to western blot for ERα degradation.
Analysis of protein ubiquitination
HEK293 cells were transfected with 4 ug ERα (or ERα 302/302AA mutant) plasmid together with 4 ug Flag-SHARPIN or empty Flag vector. After 48 h, cells were treated with 10 uM MG132 or ethanol for 6 h. Cells were directly harvested. The poly-ubiquitination of ERα was detected by western blotting analysis.
Mono-ubiquitination detection assay
To directly detect the enriched mono-ubiquitinated ERα from the cell extracts, HEK293 cells were transfected with 4 ug HA-UB-KO plasmid, 4 ug ERα (or ERα 302/302AA mutant) together with 4 ug Flag-SHARPIN or Flag-vector. After 48 h, total protein was extracted and precleared by 20ul protein A (santa cruz, SC-2001) for 2 h. The supernatant was corrected and immuno-precipitated by HA antibody. Western blot with rabbit anti-ERα antibody was performed to detect mono-ubiquitinated ERα.
Luciferase assay
The luciferase activity was done using the DualLuciferase Reporter kit (Promega, Germany). The ERE luciferase reporter was transfect together with renilla plasmid into the cells. The luciferase activity was measured after 24 h.
Chromatin immuno-precipitation (ChIP) assay
ChIP assay was performed as our previous described [8] . MCF7 cells were treated with vehicle or 10 nM estradiol for 30 minutes before crosslinking. The antibodies were used as follows: SHARPIN (AB69507, abcam), ERα (HC20, santa cruz) and rabbit IgG (sc2027, santa cruz). The sequences for ChIP primers were shown in Supplementary Table.
Immunofluorescence assay
The immunofluorescence assay was described in detail in our previous study. MCF-7 cells were treated with estradiol or vehicle for 30 min before being fixed with 4% paraformaldehyde in PBS for 10 min, permeabilized with 0.2% Triton X-100 for 5 min, and blocked by 5% BSA in PBS for 1 h. A rabbit anti-SHARPIN polyclonal antibody and mouse anti-monoclonal antibodies were used, followed by Alexa Flour 647 (Invitrogen) anti-rabbit antibody and FITC-conjugated anti-mouse antibodies (Jackson Immuno-Research, West Grove, PA).
RNA sequence analysis
The global gene expression analysis was based on RNA sequencing platform from BGI (Beijing Genomic Institute). The RNA sequence data are deposited in the Gene Expression Omnibus (GEO) database (Assessing number: GSE77261). Analysis was performed for differentially expressed genes (P < 0.01 and fold change > 2) by Ingenuity Pathway Analysis (IPA).
Analysis of gene expression in publicly available data sets
Analysis of SHARPIN expression in 62 paired normal breast tissues and breast cancer samples from The Cancer Genome Atlas (TCGA) was carried out in the statistical environment R. The relapse-free survival data of tamoxifen-only treated patients were acquired from KMPLOT database (http://kmplot.com/analysis/).
Clinical breast tumor samples
One hundred and twenty two formalin-fixed paraffin-embedded breast cancer samples were collected from the Department of Pathology, Shandong Qilu Hospital. All the breast tumors samples were examined by ERα status, PR status, HER2 status by pathological specialists. The pathological grade plus lymph node metastasis status of each sample was also examined by pathological specialists.
